Department of Psychology, UCLA Department of Psychology, PO Box 951563, Los Angeles, CA, 90095-1563, USA.
Psychopharmacology (Berl). 2013 Oct;229(3):527-38. doi: 10.1007/s00213-013-3159-9. Epub 2013 Jun 10.
Problematic drug use is associated with difficulty in exerting self-control over behaviors, and this difficulty may be a consequence of atypical morphometric characteristics that are exhibited by drug-experienced individuals. The extent to which these structural abnormalities result from drug use or reflect neurobiological risk factors that predate drug use, however, is unknown.
The purpose of this study is to determine how methamphetamine affects corticostriatal structure and how drug-induced changes relate to alterations in inhibitory control.
Structural magnetic resonance images and positron emission tomography (PET) scans, assessing dopamine D₂-like receptor and transporter availability, were acquired in monkeys trained to acquire, retain, and reverse three-choice visual discrimination problems before and after exposure to an escalating dose regimen of methamphetamine (or saline, as a control). Voxel-based morphometry was used to compare changes in corticostriatal gray matter between methamphetamine- and saline-exposed monkeys. The change in gray matter before and after the dosing regimen was compared to the change in the behavioral performance and in dopaminergic markers measured with PET.
Methamphetamine exposure, compared to saline, increased gray matter within the right putamen. These changes were positively correlated with changes in performance of methamphetamine-exposed monkeys in the reversal phase, and were negatively correlated with alterations in D₂-like receptor and DAT availability.
The results provide the first evidence that exposure to a methamphetamine dosing regimen that resembles human use alters the structural integrity of the striatum and that gray-matter abnormalities detected in human methamphetamine users are due, at least in part, to the pharmacological effects of drug experience.
药物滥用与难以控制行为有关,这种困难可能是药物滥用者表现出的非典型形态特征的结果。然而,这些结构异常是由于药物使用还是反映了药物使用之前存在的神经生物学风险因素尚不清楚。
本研究旨在确定甲基苯丙胺如何影响皮质纹状体结构,以及药物引起的变化与抑制控制的改变有何关系。
在接受递增剂量的甲基苯丙胺(或盐水,作为对照)暴露之前和之后,对经过训练以获得、保留和反转三种选择视觉辨别问题的猴子进行结构磁共振成像和正电子发射断层扫描(PET),评估多巴胺 D₂样受体和转运体的可用性。基于体素的形态计量学用于比较暴露于甲基苯丙胺和盐水的猴子之间皮质纹状体灰质的变化。将剂量方案前后的灰质变化与行为表现的变化以及 PET 测量的多巴胺能标志物的变化进行比较。
与盐水相比,甲基苯丙胺暴露增加了右侧壳核的灰质。这些变化与甲基苯丙胺暴露猴子在反转阶段的行为表现变化呈正相关,与 D₂样受体和 DAT 可用性的改变呈负相关。
这些结果首次提供了证据表明,暴露于类似于人类使用的甲基苯丙胺剂量方案会改变纹状体的结构完整性,并且在人类甲基苯丙胺使用者中检测到的灰质异常至少部分归因于药物经验的药理学作用。